Inhibition of HIF prolyl-hydroxylase domain to correct anemia in patients with chronic kidney disease

被引：3
|
作者：
Wyatt, Christina M. [1 ,2 ]
Drueke, Tilman B. [3 ,4 ]
机构：
[1] Duke Univ, Dept Med, Div Nephrol, Durham, NC USA
[2] Duke Clin Res Inst, Durham, NC USA
[3] Paris Sud Univ UPS, Hop Paul Brousse, Villejuif, France
[4] Versailles St Quentin En Yvelines Univ Paris Ile, UVSQ, Villejuif, France
来源：
KIDNEY INTERNATIONAL | 2020年 / 97卷 / 04期
关键词：
anemia; chronic kidney disease; erythropoietin; ALPHA;
D O I：
10.1016/j.kint.2019.12.005
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：639 / 642
页数：4
相关论文
共 50 条
  • [1] Prolyl-hydroxylase inhibitors for the treatment of anemia in chronic kidney disease
    McMahon, Gearoid M.
    Singh, Ajay K.
    CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2019, 28 (06): : 600 - 606
  • [2] HIF stabilization by prolyl hydroxylase inhibitors for the treatment of anemia in chronic kidney disease
    Wyatt, Christina M.
    Drueke, Tilman B.
    KIDNEY INTERNATIONAL, 2016, 90 (05) : 923 - 925
  • [3] Are prolyl-hydroxylase inhibitors potential alternative treatments for anaemia in patients with chronic kidney disease?
    Locatelli, Francesco
    Del Vecchio, Lucia
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2020, 35 (06) : 926 - 932
  • [4] Efficacy and safety of HIF prolyl-hydroxylase inhibitor vs epoetin and darbepoetin for anemia in chronic kidney disease patients not undergoing dialysis: A network meta-analysis
    Zheng, Qiyan
    Yang, Huisheng
    Sun, Luying
    Wei, Ruojun
    Fu, Xinwen
    Wang, Yahui
    Huang, Yishan
    Liu, Yu Ning
    Liu, Wei Jing
    PHARMACOLOGICAL RESEARCH, 2020, 159
  • [5] Prolyl-hydroxylase inhibition and HIF activation in osteoblasts promotes an adipocytic phenotype
    Irwin, R.
    LaPres, J. J.
    Kinser, S.
    McCabe, L. R.
    JOURNAL OF CELLULAR BIOCHEMISTRY, 2007, 100 (03) : 762 - 772
  • [6] Prolyl-hydroxylase domain inhibitors in chronic kidney disease, a promising alternative for erythropoiesis-stimulating agent
    Rubinsztajn, A.
    Fouque, D.
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2020, 76 : 28 - 30
  • [7] Comparative effectiveness and acceptability of HIF prolyl-hydroxylase inhibitors versus for anemia patients with chronic kidney disease undergoing dialysis: a systematic review and network meta-analysis
    Huang, Qiong
    You, Minling
    Huang, Weijuan
    Chen, Jian
    Zeng, Qinming
    Jiang, Longfeng
    Du, Xiuben
    Liu, Xusheng
    Hong, Ming
    Wang, Jing
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [8] Prolyl hydroxylase inhibitors for the treatment of anemia in chronic kidney disease
    Cases, A.
    Vera, M.
    Ojeda, R.
    Gorriz, J. L.
    DRUGS OF THE FUTURE, 2018, 43 (01) : 23 - 33
  • [9] Treatment of anemia associated with chronic kidney disease with the HIF prolyl hydroxylase inhibitor enarodustat: A review of the evidence
    Fujikawa, Ryo
    Nagao, Yuji
    Fujioka, Masaki
    Akizawa, Tadao
    THERAPEUTIC APHERESIS AND DIALYSIS, 2022, 26 (04) : 679 - 693
  • [10] Prolyl hydroxylase domain inhibitors as a novel therapeutic approach against anemia in chronic kidney disease
    Sugahara, Mai
    Tanaka, Tetsuhiro
    Nangaku, Masaomi
    KIDNEY INTERNATIONAL, 2017, 92 (02)
12345